Guggenheim analyst Vamil Divan raised the firm’s price target on Vera Therapeutics (VERA) to $61 from $59 and keeps a Buy rating on the shares. Vera’s strengthened balance sheet, bolstered by two 2024 equity offerings that amount to about $600M in net proceeds, positions it well through potential 2026 commercialization, the analyst tells investors in a post-Q4 note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook
- Vera Therapeutics selloff a buying opportunity, says Evercore ISI
- Buy Rating for Vera Therapeutics: Atacicept’s Unique Potential in the IgAN Market
- Vera Therapeutics pullback a buying opportunity, says Cantor Fitzgerald
- Vera Therapeutics’ Atacicept Positioned for Growth Amid Market Overreaction to Otsuka’s Sibeprenlimab